CNS Pharmaceuticals (NASDAQ:CNSP) Announces Earnings Results, Misses Expectations By $0.14 EPS

CNS Pharmaceuticals (NASDAQ:CNSP) issued its earnings results on Wednesday. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14), FiscalAI reports.

CNS Pharmaceuticals Stock Performance

Shares of CNS Pharmaceuticals stock traded down $0.34 during midday trading on Wednesday, reaching $5.16. 4,285 shares of the company’s stock traded hands, compared to its average volume of 600,610. CNS Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $10.59. The company’s 50 day simple moving average is $4.96 and its 200 day simple moving average is $4.19. The company has a market cap of $7.54 million, a price-to-earnings ratio of -0.17 and a beta of 3.05.

Insider Transactions at CNS Pharmaceuticals

In other CNS Pharmaceuticals news, Director Faith L. Charles bought 7,100 shares of the stock in a transaction on Monday, May 18th. The shares were purchased at an average cost of $4.79 per share, with a total value of $34,009.00. Following the completion of the transaction, the director directly owned 7,100 shares of the company’s stock, valued at $34,009. This represents a ? increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.01% of the company’s stock.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter worth approximately $71,000. Ikarian Capital LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter worth $241,000. Finally, Armistice Capital LLC acquired a new stake in shares of CNS Pharmaceuticals in the second quarter worth $335,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.